Category Archives: Global News Feed

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -

Original post:
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022. In addition, the Company provided an overview of recent corporate developments.

Continue reading here:
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

MIAMI, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was made as a material inducement to the five employees’ entry into employment with the Company.

More here:
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022

See the original post here:
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, yesterday presented positive data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM) at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases. The conference is co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) and is being held August 12-13, 2022 in Toronto, Canada.

Here is the original post:
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

Management to host conference call and webcast at 4:30 pm ET

Read more here:
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s management will participate in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, to be held virtually and in New York City from August 8-9, 2022.

More here:
Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors

Go here to read the rest:
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Total Revenue up 51% and Product Revenue up 135% YOY

Read the original post:
Codexis Reports Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.

Read the original post:
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results